secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001140361-23-050682
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dr. James Bristol appointed to board of Eterna Therapeutics
-----------------------------------------------------------

- Dr. James Bristol appointed as director effective Oct 30, 2023; term until 2024 annual meeting.
- Bristol appointed to Audit, Compensation, and Nominating/Corporate Governance Committees.
- Board determined Bristol is independent under Nasdaq rules; no material transactions with the Company.
- Standard non-employee director compensation and indemnification agreement to be entered into.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123050682/0001140361-23-050682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123050682/ef20013697_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-050682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer